How Anthem may win by sitting out healthcare’s merger mania

Four of the five major health insurers in the U.S. are involved in major mergers and acquisitions discussed over the past few months. The lone exception has been Anthem, which may put the company in a stronger position, according to the Wall Street Journal.

While Humana is talking with Walmart, Aetna is waiting to be bought by CVS Health, Cigna Is looking to buy Express Scripts and UnitedHealth has been expanding its provider portfolio, Anthem has been largely silent on any major deals. There’s no guarantee any of these transactions will be completed—just like Anthem’s abandoned merger of Cigna—and investors have been largely on lukewarm on these proposed vertical integrations. Cigna, for example, has seen its stock price fall 13 percent in the past month.

By waiting to see how the dust settles, Anthem has many options available for future growth. WSJ’s Charley Grant noted its net debt sits at roughly 35 percent of total capital, leaving room for expansion on the balance sheet. If it chooses to be more aggressive with acquisitions, it could start by targeting smaller insurers like WellCare, Centene and Molina Healthcare.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.